Journal article
Protein kinase C-beta II expression in diffuse large B-cell lymphoma predicts for inferior outcome of anthracycline-based chemotherapy with and without rituximab
Kritika Chaiwatanatorn, Georgia Stamaratis, Ken Opeskin, Frank Firkin, Harshal Nandurkar
LEUKEMIA & LYMPHOMA | TAYLOR & FRANCIS LTD | Published : 2009
Abstract
Protein kinase C-beta II (PKC-beta II) expression has been reported to indicate inferior prognosis in diffuse large B-cell lymphoma (DLBCL) treated with anthracycline-based chemotherapy. This study compared prognostic significance of immunohistochemically determined PKC-beta II expression in de novo DLBCL treated with cyclophosphamide, doxorubicin, vincristine and prednisolone (CHOP) chemotherapy with and without rituximab. Outcomes were assessed in 80 consecutive patients, 48 treated with CHOP, and 32 with rituximab plus CHOP (R-CHOP). PKC-beta II expression correlated with inferior overall survival (OS) and progression-free survival (PFS) in CHOP-treated patients with low-risk Internationa..
View full abstractGrants
Funding Acknowledgements
This research was supported by the NHMRC postgraduate scholarship, Kanamatsu scholarship, Carty-Lew Foundation and unrestricted grant from Novartis Pharmaceutical Australia.